Cargando…

Optimizing Tuberculosis Case Detection through a Novel Diagnostic Device Placement Model: The Case of Uganda

BACKGROUND: Xpert MTB/RIF (Xpert) is being widely adopted in high TB burden countries. Analysis is needed to guide the placement of devices within health systems to optimize the tuberculosis (TB) case detection rate (CDR). METHODS: We used epidemiological and operational data from Uganda (139 sites...

Descripción completa

Detalles Bibliográficos
Autores principales: Pho, Mai T., Deo, Sarang, Palamountain, Kara M., Joloba, Moses Lutaakome, Bajunirwe, Francis, Katamba, Achilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382196/
https://www.ncbi.nlm.nih.gov/pubmed/25830297
http://dx.doi.org/10.1371/journal.pone.0122574
_version_ 1782364569973293056
author Pho, Mai T.
Deo, Sarang
Palamountain, Kara M.
Joloba, Moses Lutaakome
Bajunirwe, Francis
Katamba, Achilles
author_facet Pho, Mai T.
Deo, Sarang
Palamountain, Kara M.
Joloba, Moses Lutaakome
Bajunirwe, Francis
Katamba, Achilles
author_sort Pho, Mai T.
collection PubMed
description BACKGROUND: Xpert MTB/RIF (Xpert) is being widely adopted in high TB burden countries. Analysis is needed to guide the placement of devices within health systems to optimize the tuberculosis (TB) case detection rate (CDR). METHODS: We used epidemiological and operational data from Uganda (139 sites serving 87,600 individuals tested for TB) to perform a model-based comparison of the following placement strategies for Xpert devices: 1) Health center level (sites ranked by size from national referral hospitals to health care level III centers), 2) Smear volume (sites ranked from highest to lowest volume of smear microscopy testing), 3) Antiretroviral therapy (ART) volume (sites ranked from greatest to least patients on ART), 4) External equality assessment (EQA) performance (sites ranked from worst to best smear microscopy performance) and 5) TB prevalence (sites ranked from highest to lowest). We compared two clinical algorithms, one where Xpert was used only for smear microscopy negative samples versus another replacing smear microscopy. The primary outcome was TB CDR; secondary outcomes were detection of multi-drug resistant TB, number of sites requiring device placement to achieve specified rollout coverage, and cost. RESULTS: Placement strategies that prioritized sites with higher TB prevalence maximized CDR, with an incremental rate of 6.2–12.6% compared to status quo (microscopy alone). Diagnosis of MDR-TB was greatest in the TB Prevalence strategy when Xpert was used in place of smear microscopy. While initial implementation costs were lowest in the Smear Volume strategy, cost per additional TB case detected was lowest in the TB prevalence strategy. CONCLUSION: In Uganda, placement of Xpert devices in sites with high TB prevalence yielded the highest TB CDR at the lowest cost per additional case diagnosed. These results represent novel use of program level data to inform the optimal placement of new technology in resource-constrained settings.
format Online
Article
Text
id pubmed-4382196
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43821962015-04-09 Optimizing Tuberculosis Case Detection through a Novel Diagnostic Device Placement Model: The Case of Uganda Pho, Mai T. Deo, Sarang Palamountain, Kara M. Joloba, Moses Lutaakome Bajunirwe, Francis Katamba, Achilles PLoS One Research Article BACKGROUND: Xpert MTB/RIF (Xpert) is being widely adopted in high TB burden countries. Analysis is needed to guide the placement of devices within health systems to optimize the tuberculosis (TB) case detection rate (CDR). METHODS: We used epidemiological and operational data from Uganda (139 sites serving 87,600 individuals tested for TB) to perform a model-based comparison of the following placement strategies for Xpert devices: 1) Health center level (sites ranked by size from national referral hospitals to health care level III centers), 2) Smear volume (sites ranked from highest to lowest volume of smear microscopy testing), 3) Antiretroviral therapy (ART) volume (sites ranked from greatest to least patients on ART), 4) External equality assessment (EQA) performance (sites ranked from worst to best smear microscopy performance) and 5) TB prevalence (sites ranked from highest to lowest). We compared two clinical algorithms, one where Xpert was used only for smear microscopy negative samples versus another replacing smear microscopy. The primary outcome was TB CDR; secondary outcomes were detection of multi-drug resistant TB, number of sites requiring device placement to achieve specified rollout coverage, and cost. RESULTS: Placement strategies that prioritized sites with higher TB prevalence maximized CDR, with an incremental rate of 6.2–12.6% compared to status quo (microscopy alone). Diagnosis of MDR-TB was greatest in the TB Prevalence strategy when Xpert was used in place of smear microscopy. While initial implementation costs were lowest in the Smear Volume strategy, cost per additional TB case detected was lowest in the TB prevalence strategy. CONCLUSION: In Uganda, placement of Xpert devices in sites with high TB prevalence yielded the highest TB CDR at the lowest cost per additional case diagnosed. These results represent novel use of program level data to inform the optimal placement of new technology in resource-constrained settings. Public Library of Science 2015-04-01 /pmc/articles/PMC4382196/ /pubmed/25830297 http://dx.doi.org/10.1371/journal.pone.0122574 Text en © 2015 Pho et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Pho, Mai T.
Deo, Sarang
Palamountain, Kara M.
Joloba, Moses Lutaakome
Bajunirwe, Francis
Katamba, Achilles
Optimizing Tuberculosis Case Detection through a Novel Diagnostic Device Placement Model: The Case of Uganda
title Optimizing Tuberculosis Case Detection through a Novel Diagnostic Device Placement Model: The Case of Uganda
title_full Optimizing Tuberculosis Case Detection through a Novel Diagnostic Device Placement Model: The Case of Uganda
title_fullStr Optimizing Tuberculosis Case Detection through a Novel Diagnostic Device Placement Model: The Case of Uganda
title_full_unstemmed Optimizing Tuberculosis Case Detection through a Novel Diagnostic Device Placement Model: The Case of Uganda
title_short Optimizing Tuberculosis Case Detection through a Novel Diagnostic Device Placement Model: The Case of Uganda
title_sort optimizing tuberculosis case detection through a novel diagnostic device placement model: the case of uganda
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382196/
https://www.ncbi.nlm.nih.gov/pubmed/25830297
http://dx.doi.org/10.1371/journal.pone.0122574
work_keys_str_mv AT phomait optimizingtuberculosiscasedetectionthroughanoveldiagnosticdeviceplacementmodelthecaseofuganda
AT deosarang optimizingtuberculosiscasedetectionthroughanoveldiagnosticdeviceplacementmodelthecaseofuganda
AT palamountainkaram optimizingtuberculosiscasedetectionthroughanoveldiagnosticdeviceplacementmodelthecaseofuganda
AT jolobamoseslutaakome optimizingtuberculosiscasedetectionthroughanoveldiagnosticdeviceplacementmodelthecaseofuganda
AT bajunirwefrancis optimizingtuberculosiscasedetectionthroughanoveldiagnosticdeviceplacementmodelthecaseofuganda
AT katambaachilles optimizingtuberculosiscasedetectionthroughanoveldiagnosticdeviceplacementmodelthecaseofuganda